Argenx Of The Netherlands Has Licensed A Drug For Blood Cancers To Johnson & Johnson In A Deal That Gives It A Hefty $300M Upfront Payment, Plus A $200M Equity Investment By The Big Pharma Company.The Deal Centres On Cusatuzumab (Argx-110), A Cd70-Targeting Antibody That Is Being Developed For The Treatment Of Acute Myeloid Leukaemia (Aml), Myelodysplastic Syndrome (Mds) And Other Haematological Cancers And Is In Phase 1/2 Testing. It Also Covers Next-Generation Anti-Cd70 Drugs.All Told, Milestone Payments Of $1.3Bn Could Swell J&J
